The phrase "assumed lifetime" is correct and usable in written English.
It can be used in contexts where you are discussing the expected duration or lifespan of an object, concept, or individual based on certain assumptions.
Example: "The assumed lifetime of this product is five years, after which it may require replacement."
Alternatives: "expected lifespan" or "projected duration".
Note that the assumed lifetime is for 15 years while the CER income is only scheduled until the 11th year.
It is a copper indium gallium selenide (CIGS) module with an assumed lifetime of 20 years and a derating factor of 80%, including, e.g., aging, wiring, connection losses, dust, and shading[27].
The total NPV result of Nangong composting plant is −294 million USD or about −545,538 per ton waste treatment capacity, CBR is 0.77 and amortization time cannot be achieved in the 15 years assumed lifetime.
As a result, only the 100% wind turbines scenario reached a payback time which is shorter than the assumed lifetime, 5.7 years for the lower bound of capital cost and 10.5 years for the upper bound.
Firstly, we assumed lifetime risk was calculated in screened women only rather than taking a population perspective as for the current analysis.
Although intravenous exposure to DEHP through the ECMO circuit or other intravenous routes exceeds recommended oral exposure limits, it is difficult to directly compare the two because one is an assumed lifetime daily oral exposure and the other an acute temporary exposure during ECMO therapy.
27 Capital costs were discounted and annualized by using a 3% discount rate and assumed lifetimes for equipment based on expert opinion and past literature.
Assuming lifetime exposure and a proposed cancer slope factor of 25.7 per milligram per kilogram of body weight per day, this increase in arsenic exposure could result in 3.7 additional lifetime bladder and lung cancer cases per 100,000 exposed persons.
Cost/QALY was highest in scenarios assuming lifetime dronedarone therapy, no cardiovascular mortality benefit, no cost associated with AF/AFL recurrence on standard care, and when discounting of 5% was compared with 0%.
This analysis also demonstrated that the cost/QALY was highest in scenarios assuming lifetime therapy with dronedarone, no cardiovascular mortality benefit, no cost associated with AF recurrence on standard of care, and when discounting of 5% was compared with 0%.
Because the consequences of stroke and haemorrhage could be life long, the model assumed a lifetime horizon (up to 100 years of age) in the base case.
